ATE153858T1 - Ligand für das neu-gen-produkt - Google Patents

Ligand für das neu-gen-produkt

Info

Publication number
ATE153858T1
ATE153858T1 AT91908319T AT91908319T ATE153858T1 AT E153858 T1 ATE153858 T1 AT E153858T1 AT 91908319 T AT91908319 T AT 91908319T AT 91908319 T AT91908319 T AT 91908319T AT E153858 T1 ATE153858 T1 AT E153858T1
Authority
AT
Austria
Prior art keywords
pct
sec
activity
tyrosine kinase
disclosed
Prior art date
Application number
AT91908319T
Other languages
English (en)
Inventor
Mark I Greene
Kunio Dobashi
James G Davis
Junji Hamuro
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE153858T1 publication Critical patent/ATE153858T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT91908319T 1990-04-06 1991-04-04 Ligand für das neu-gen-produkt ATE153858T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50583790A 1990-04-06 1990-04-06

Publications (1)

Publication Number Publication Date
ATE153858T1 true ATE153858T1 (de) 1997-06-15

Family

ID=24012070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908319T ATE153858T1 (de) 1990-04-06 1991-04-04 Ligand für das neu-gen-produkt

Country Status (7)

Country Link
US (1) US5464751A (de)
EP (1) EP0527802B1 (de)
JP (1) JPH0776238B2 (de)
AT (1) ATE153858T1 (de)
CA (1) CA2079585C (de)
DE (1) DE69126430T2 (de)
WO (1) WO1991015230A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE182152T1 (de) * 1991-01-14 1999-07-15 Univ Georgetown Wachstumsfaktor-ligand, der an den erbb-2- rezeptor bindet und die zellulären reaktionen induziert
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7094749B1 (en) 1991-04-10 2006-08-22 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7285531B1 (en) 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
WO1994008007A1 (en) * 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
DE60033658T2 (de) * 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2110138A1 (de) * 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
EP1280923A2 (de) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU8433901A (en) * 2000-09-07 2002-03-22 Virtual Publishing Company Ltd An electronic publication and methods and components thereof
EP1572972A4 (de) * 2002-11-21 2007-11-21 Genentech Inc Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease

Also Published As

Publication number Publication date
EP0527802B1 (de) 1997-06-04
US5464751A (en) 1995-11-07
DE69126430T2 (de) 1997-09-18
EP0527802A4 (en) 1993-05-26
CA2079585C (en) 1997-01-07
DE69126430D1 (de) 1997-07-10
JPH06500072A (ja) 1994-01-06
CA2079585A1 (en) 1991-10-07
WO1991015230A1 (en) 1991-10-17
EP0527802A1 (de) 1993-02-24
JPH0776238B2 (ja) 1995-08-16

Similar Documents

Publication Publication Date Title
DE69126430D1 (de) Ligand für das neu-gen-produkt
Boukamp et al. Mesenchyme-mediated and endogenous regulation of growth and differentiation of human skin keratinocytes derived from different body sites
Haralson et al. Chinese hamster lung cells synthesize and confine to the cellular domain a collagen composed solely of B chains.
Haigler et al. Production and characterization of antibody blocking epidermal growth factor: receptor interactions
Holden et al. Human and mouse embryonal carcinoma cells in culture share an embryonic antigen (F9)
ES2164633T3 (es) Genes vegetales sinteticos y procedimiento para su preparacion.
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
MY102472A (en) Preparation of funtional human urokinase proteins.
Anderson et al. Normal fibroblasts responding to anoxia exhibit features of the malignant phenotype
ATE199095T1 (de) Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf)
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
Villee et al. Effect of glucose and insulin on collagen secretion by human skin fibroblasts in vitro
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
ATE188736T1 (de) Endothelin-dna und verwendung davon
KR840001836A (ko) 생리활성 물질의 제법
Rutka et al. Characterization of normal human brain cultures. Evidence for the outgrowth of leptomeningeal cells.
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
Minafra et al. Quantitative determination of collagen types present in the ductal infiltrating carcinoma of human mammary gland
Salzman Animal Cell Cultures: Tissue culture is a powerful tool in the study of nutrition, physiology, virology, and genetics.
Lovell et al. Changes in the collagen of synovial membrane in rheumatoid arthritis and effect of D-penicillamine
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
ITRM920506A1 (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
KR870005645A (ko) 신규세포 생장조절 인자
Siraganian et al. Evidence that the “mouse mastocytoma” cell line (MCT-1) is of rat origin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties